AMAdam D. McIntyre

Adam D. McIntyre

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Adam D. McIntyre has a total of 89 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Genetic Testing in Adults over 50 Years with Chronic Kidney Disease: Diagnostic Yield and Clinical Implications in a Specialized Kidney Genetics Clinic

    by Clara Schott, Mohammad Alajmi, Mohammad Bukhari, Sydney Relouw, Jian Wang, Adam D. McIntyre, Cadence Baker, Samantha Colaiacovo, Carla Campagnolo, Gabriela Almada Offerni, et al.

    Background: Genetic causes of chronic diseases, once considered rare in adult-onset disease, now account for between 10 and 20% of cases of chronic kidney disease (CKD). Confirming a genetic diagnosis can influence disease management; however, the utility of genetic testing in older adults remains poorly understood, partly due to age-based restrictions on testing access. To better evaluate the diagnostic yield and clinical utility of genetic testing in this population, we analyzed data from adults aged ≥50 years with CKD who were assessed in a specialized kidney genetics clinic. Methods: We studied a cohort of 125 adults with CKD aged ≥50 years at the time of genetic testing. Genetic testing included gene panels targeting disease-related genes based on clinical phenotype, and/or exome sequencing for additional monogenic causes if the initial panel testing was inconclusive. Results: Pathogenic variants in disease-related genes were identified in 38% of patients. The highest diagnostic yield (48%) was in patients aged 50–54 years. The most common diagnosis post-testing was glomerulopathies (32%). Clinical utility, shown through the case series, included modifications to treatment and clinical management, as well as a reduction in the diagnostic odyssey. Conclusions: Our findings from a dedicated Kidney Genetics Clinic show that genetic testing in adults ≥50 years with CKD has significant diagnostic and clinical utility. These results support guideline recommendations that there should be no upper age limit for genetic testing. Future research in unselected CKD populations is needed to establish the broader applicability and feasibility of genetic testing in older adults.


  • Open Access

    Lipoprotein Lipase: Structure, Function, and Genetic Variation

    by Shehan D. Perera, Jian Wang, Adam D. McIntyre, Robert A. Hegele

    Biallelic rare pathogenic loss-of-function (LOF) variants in lipoprotein lipase (LPL) cause familial chylomicronemia syndrome (FCS). Heterozygosity for these same variants is associated with a highly variable plasma triglyceride (TG) phenotype ranging from normal to severe hypertriglyceridemia (HTG), with longitudinal variation in phenotype severity seen often in a given carrier. Here, we provide an updated overview of genetic variation in LPL in the context of HTG, with a focus on disease-causing and/or disease-associated variants. We provide a curated list of 300 disease-causing variants discovered in LPL, as well as an exon-by-exon breakdown of the LPL gene and protein, highlighting the impact of variants and the various functional residues of domains of the LPL protein. We also provide a curated list of variants of unknown or uncertain significance, many of which may be upgraded to pathogenic/likely pathogenic classification should an additional case and/or segregation data be reported. Finally, we also review the association between benign/likely benign variants in LPL, many of which are common polymorphisms, and the TG phenotype.


  • Open Access

    Lipoprotein Lipase: Structure, Function, and Genetic Variation

    by Shehan D. Perera, Jian Wang, Adam D. McIntyre, Robert A. Hegele

    Biallelic rare pathogenic loss-of-function (LOF) variants in lipoprotein lipase (LPL) cause familial chylomicronemia syndrome (FCS). Heterozygosity for these same variants is associated with a highly variable plasma triglyceride (TG) phenotype ranging from normal to severe hypertriglyceridemia (HTG), with longitudinal variation of phenotype severity seen often in a given carrier. Here we provide an updated overview of genetic variation in LPL in the context of HTG, with a focus on disease-causing and/or disease-associated variants. We provide a curated list of 300 disease-causing variants discovered in LPL, as well as an exon-by-exon breakdown of the LPL gene and protein, highlighting the impact of variants and the various functional residues of domains of the LPL protein. We also provide a curated list of variants of unknown or uncertain significance, many of which may be upgraded to pathogenic/likely pathogenic classification should additional case and/or segregation data be reported. Finally, we also review the association between benign/likely benign variants in LPL, many of which are common polymorphisms, and TG phenotype.

  • Open Access

    Phenotype in Individuals with Heterozygous Rare Variants in LIPC Encoding Hepatic Lipase

    by Erin O. Jacob, Jian Wang, Adam D. McIntyre, Robert A. Hegele

    Hepatic lipase deficiency is a rare genetic condition caused by biallelic loss-of-function variants in the LIPC gene encoding hepatic lipase. These variants reduce or abolish the protein’s lipolytic activity, resulting in elevated plasma lipids. The condition is classified as autosomal recessive, since dyslipidemia is inconsistently observed in heterozygous patients with only one LIPC variant. However, this has been concluded from historical studies encompassing a few families and having very small sample sizes. Here, we conduct a retrospective chart review of 46 heterozygous subjects, each harboring one rare pathogenic LIPC variant. We compare plasma levels of total cholesterol, low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), triglycerides, and apolipoprotein B to those of matched controls without LIPC variants. Variant pathogenicity is classified according to the guidelines of the American College of Medical Genetics and Genomics. We observe that levels of total cholesterol, LDL-C, and triglycerides are significantly elevated in the LIPC variant heterozygotes, but HDL-C and apolipoprotein B are not. When filtering solely with respect to pathogenic or likely pathogenic variants, all lipid variables emerge as significantly elevated compared to controls. Thus, hepatic lipase deficiency may not necessarily be a recessive condition, but perhaps semi-dominant since individuals with one variant are phenotypically distinct from the controls. These hypothesis-generating findings regarding LIPC genetic variations observed in a clinical cohort should be evaluated in larger populations and databases.


  • Open Access

    Evidence of synergism among three genetic variants in a patient with LMNA-related lipodystrophy and amyotrophic lateral sclerosis leading to a remarkable nuclear phenotype

    by Kathryn Volkening, Sali M. K. Farhan, Jessica Kao, Cheryl Leystra-Lantz, Lee Cyn Ang, Adam McIntyre, Jian Wang, Robert A. Hegele, Michael J. Strong

    Neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS), can be clinically heterogeneous which may be explained by the co-inheritance of multiple genetic variants that modify the clinical course. In this study we examine variants in three genes in a family with one individual presenting with ALS and lipodystrophy. Sequencing revealed a p.Gly602Ser variant inLMNA, and two additional variants, one each inSETX(g.intron10-13delCTT) andFUS(p.Gly167_Gly168del). These latter genes have been linked to ALS. All family members were genotyped and each variant, and each combination of variants detected, were functionally evaluated in vitro regarding effects on cell survival, expression patterns and cellular phenotype. Muscle biopsy retrieved from the individual with ALS showed leakage of chromatin from the nucleus, a phenotype that was recapitulated in vitro with expression of all three variants simultaneously. Individually expressed variants gave cellular phenotypes there were unremarkable. Interestingly theFUSvariant appears to be protective against the effects of theSETXand theLMNAvariants on cell viability and may indicate loss of interaction of FUS with SETX and/or R-loops. We conclude that these findings support genetic modifications as an explanation of the clinical heterogeneity observed in human disease.


  • Interrogation of selected genes influencing serum LDL-Cholesterol levels in patients with well characterized NAFLD

    by Eduardo Vilar-Gomez, Samer Gawrieh, Tiebing Liang, Adam D. McIntyre, Robert A. Hegele, Naga Chalasani


  • Role of Common Genetic Variation in Lone Atrial Fibrillation

    by Julieta Lazarte, Jacqueline S. Dron, Adam D. McIntyre, Allan C. Skanes, Lorne J. Gula, Anthony S. Tang, Rafik Tadros, Zachary W. Laksman, Robert A. Hegele, Jason D. Roberts


  • Simplifying Detection of Copy-Number Variations in Maturity-Onset Diabetes of the Young

    by Amanda J. Berberich, Jian Wang, Henian Cao, Adam D. McIntyre, Tamara Spaic, David B. Miller, Suzanne Stock, Celine Huot, Robert Stein, Joan Knoll, et al.


  • Open Access

    Combined hyperlipidemia is genetically similar to isolated hypertriglyceridemia

    by Praneet K. Gill, Jacqueline S. Dron, Amanda J. Berberich, Jian Wang, Adam D. McIntyre, Henian Cao, Robert A. Hegele


  • Ancestry-specific profiles of genetic determinants of severe hypertriglyceridemia

    by Praneet K. Gill, Jacqueline S. Dron, Allison A. Dilliott, Adam D. McIntyre, Henian Cao, Jian Wang, Irina G. Movsesyan, Mary J. Malloy, Clive R. Pullinger, John P. Kane, et al.